High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Conjugation of therapeutic proteins with high molecular weight polyethylene glycols (HMW PEGs) is used to extend the half-life of biologics. To evaluate the effects of HMW PEGs in animals, we used an immunohistochemical procedure to study the tissue distribution and toxicity of unconjugated HMW PEGs in rats given 100 mg/kg 10K PEG, 20K PEG, or 40K PEG intravenously. Both the PEG cellular distribution and the histology were different between groups. In 10K PEG and 20K PEG groups, PEG immunoreactivity was most prominent in the renal tubule epithelium and in alveolar macrophages and hepatic Kupffer cells and cellular vacuolation was absent. In contrast, rats given 40K PEG had strong PEG immunoreactivity in splenic subcapsular red pulp macrophages, renal interstitial macrophages, and choroid plexus epithelial cells that was frequently associated with cytoplasmic vacuolation. While the vacuolation appeared to be an adaptive response, there was focal renal tubular epithelial degeneration associated with strong PEG immunoreactivity in one rat given 40K PEG. These data indicate that both the tissue distribution and the vacuolation observed with unconjugated HMW PEGs are markedly influenced by the molecular weight of the PEG and that when vacuolation is observed it is likely an adaptive change that is associated with PEG cytoplasmic immunoreactivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polyethyleneglycol (PEG) (also known as poly(ethylene oxide) (PEO)) has been the most frequently employed hydrophilic, shell-forming block in polymeric micelles thus far due to its safety profile in humans and classification as “Generally Regarded as Safe” (GRAS) by the US Food and Drug Administration (USFDA).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [66]
In the citing paper
“Low molecular weight PEG and PEG-conjugates of 20 kDa or less, have a low incidence of toxicity [66–68].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [66]
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 4×
“PEGylation using high molecular weight polyethylene glycols (HMW PEGs 10 kDa) is an important tactic employed to increase half-life, reduce renal clearance, and potentially decrease the immunogenicity of therapeutic proteins (Harris and Chess 2003; Webster et al. 2009).”
BackgroundMethodInfluentialQuantification of histochemical staining by color deconvolution.
Ruifrok, A. C. C., & Johnston, D. A. (2001) · PubMed · Cited by 2,568
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221 · cited 1×
“Interestingly, in the mouse, there is a large subcapsular specific pool of reserve Ly6Chigh monocytes that are phagocytic and respond to systemic demand in inflammation (Swirski et al. 2009).”
BackgroundCell biology of the glomerular podocyte
Pavenstädt, H., Kriz, W., & Kretzler, M. (2003) · Physiological Reviews · doi:10.1152/physrev.00020.2002 · Cited by 1,499 · cited 1×
“The podocyte wraps around the basal lamina of the glomerular capillary endothelial cell to form a filtration slit that allows only small molecules to pass and has a high level of endocytic and catabolic activity as indicated by a large number of lysosomes (Pavenstadt, Kriz, and Kretzler 2003).”
BackgroundYamaoka, T., Tabata, Y., & Ikada, Y. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830432 · Cited by 748 · cited 2×
“Higher molecular weight PEGs are retained in the blood longer while lower molecular weight PEGs have a larger volume of distribution (Yamaoka, Tabata, and Ikada 1994).”
BackgroundNormal structure, function, and histology of the spleen
Cesta, M. F. (2006) · Toxicologic Pathology · doi:10.1080/01926230600867743 · Cited by 731 · cited 1×
“This is consistent with the leakiness of the splenic red pulp sinuses, which facilitates macrophage removal of senescent red blood cells or blood particulates no matter the molecular weight or size (Cesta 2006).”
ResultArmstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699 · cited 2×
“2009) and clinical reports of anti-PEG antibodies that reduce the effectiveness of treatment (Armstrong et al. 2007).”
BackgroundBendele, A. M., Seely, J., Richey, C., Sennello, G., & Shopp, G. M. (1998) · Toxicological Sciences · doi:10.1006/toxs.1997.2396 · Cited by 279 · cited 14×
“For all three HMW PEGs in this study, we administered 100 mg/kg intravenously to approximate ‘‘high’’ doses evaluated in toxicology studies in our laboratory as well as by other groups testing PEGylated biologics (BLA #125160 2006; Bendele et al. 1998; Young et al. 2007; Webster et al. 2009).”
BackgroundMethodResultInfluentialWebster, R., Elliott, V., Park, B. K., Walker, D., Hankin, M., & Taupin, P. (2009) · PEGylated Protein Drugs: Basic Science and Clinical Applications · doi:10.1007/978-3-7643-8679-5_8 · Cited by 187 · cited 16×
“For all three HMW PEGs in this study, we administered 100 mg/kg intravenously to approximate ‘‘high’’ doses evaluated in toxicology studies in our laboratory as well as by other groups testing PEGylated biologics (BLA #125160 2006; Bendele et al. 1998; Young et al. 2007; Webster et al. 2009).”
BackgroundMethodResultInfluentialAnalytical Measurement of PEGylated Molecules
Cheng, T., Chuang, K.-H., Chen, B., & Roffler, S. R. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200478w · Cited by 145 · cited 3×
“These antibodies were developed to bind either the PEG molecule itself, the backbone linker of the PEG, or the terminal PEG methoxy group (Cheng et al. 2012; Webster et al. 2009).”
BackgroundMethodExpanding the definition of the blood-brain barrier to protein.
Broadwell, R. D., & Salcman, M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.12.7820 · Cited by 132 · cited 2×
“The pericyte is a macrophage-derived cell located on the abluminal surfaces of cerebral capillaries that can govern entry of large molecules (e.g., 40KPEG) into the brain (Broadwell and Salcman 1981).”
BackgroundWhite, C. A., Zhang, J., Salamonsen, L. A., Baca, M., Fairlie, W. D., Metcalf, D., Nicola, N. A., Robb, L., & Dimitriadis, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710110104 · Cited by 100 · cited 1×
“Recently, anti-PEG antibodies have been developed by several groups and their potential utility as IHC reagents demonstrated in published pharmacology studies (Hu et al. 2011; Menkhorst et al. 2009; White et al. 2007).”
BackgroundAbsorption of Polyethylene Glycol (PEG) Polymers: The Effect of PEG Size on Permeability
Gursahani, H., Riggs, J. A., Pfeiffer, J. W., Lechuga‐Ballesteros, D., & Fishburn, C. S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21635 · Cited by 70 · cited 6×
“Both alveolar macrophage and Kupffer cell populations are behind endothelial barriers that are size-permissive for the passage of PEG or PEG (Gursahani et al. 2009).”
BackgroundInfluentialIL11 Antagonist Inhibits Uterine Stromal Differentiation, Causing Pregnancy Failure in Mice1
Menkhorst, E. M., Salamonsen, L. A., Robb, L., & Dimitriadis, E. (2009) · Biology of Reproduction · doi:10.1095/biolreprod.108.073601 · Cited by 60 · cited 1×
“Recently, anti-PEG antibodies have been developed by several groups and their potential utility as IHC reagents demonstrated in published pharmacology studies (Hu et al. 2011; Menkhorst et al. 2009; White et al. 2007).”
BackgroundYoung, M. A., Malavalli, A., Winslow, N., Vandegriff, K. D., & Winslow, R. M. (2007) · Translational research · doi:10.1016/j.trsl.2006.09.007 · Cited by 55 · cited 5×
“For all three HMW PEGs in this study, we administered 100 mg/kg intravenously to approximate ‘‘high’’ doses evaluated in toxicology studies in our laboratory as well as by other groups testing PEGylated biologics (BLA #125160 2006; Bendele et al. 1998; Young et al. 2007; Webster et al. 2009).”
BackgroundMethodResultInfluentialElliott, V. L., Edge, G. T., Phelan, M. M., Lian, L., Webster, R., Finn, R. F., Park, B. K., & Kitteringham, N. R. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200587m · Cited by 33 · cited 3×
“…tissues or fluids, an analysis of the effects of different HMW PEGs on cellular PEG distribution and PEG-related toxicologic findings has not been done, likely because a PEG IHC technique was unavailable (Cheng et al. 2012; Elliott et al. 2012; Tsai, Cheng, and Roffler 2001; Webster et al. 2009).”
BackgroundMethodIn Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a
Hu, X. S., Olivier, K., Polack, E., Crossman, M., Zokowski, K., Gronke, R. S., Parker, S. E., Li, Z., Nestorov, I. A., Baker, D. P., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180661 · Cited by 31 · cited 1×
“Recently, anti-PEG antibodies have been developed by several groups and their potential utility as IHC reagents demonstrated in published pharmacology studies (Hu et al. 2011; Menkhorst et al. 2009; White et al. 2007).”
BackgroundSensitive Measurement of Polyethylene Glycol-Modified Proteins
Tsai, N., Cheng, T., & Roffler, S. R. (2001) · BioTechniques · doi:10.2144/01302rr03 · Cited by 26 · cited 1×
“…tissues or fluids, an analysis of the effects of different HMW PEGs on cellular PEG distribution and PEG-related toxicologic findings has not been done, likely because a PEG IHC technique was unavailable (Cheng et al. 2012; Elliott et al. 2012; Tsai, Cheng, and Roffler 2001; Webster et al. 2009).”
Research works printed but not linked: 2
- 10.1093/toxsci/42.2.152 · doi:10.1093/toxsci/42.2.152 · Paper page
- Ruifrok A. C., 2001, Anal Quant Cytol Histol, 23, 291
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Materials and methods for delivery of biological drugs
Zelikin, A. N., Ehrhardt, C., & Healy, A. M. (2016) · Nature Chemistry · doi:10.1038/nchem.2629 · Cited by 315
Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications
Englert, C., Brendel, J. C., Majdanski, T. C., Yildirim, T., Schubert, S., Gottschaldt, M., Windhab, N., & Schubert, U. S. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.005 · Cited by 247
Su, C., Liu, Y., Li, R., Wu, W., Fawcett, J. P., & Gu, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.008 · Cited by 200
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development
Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., Depelchin, B. O., Irizarry Rovira, A. R., Dill-Morton, L., Lane, J. H., et al. (2015) · Toxicologic Pathology · doi:10.1177/0192623315591171 · Cited by 158
“Rudmann et al. (2013) reported a high incidence of renal tubular vacuolation after administration of unconjugated 40-kDa PEG iv (5 of 5 rats), but only 1 of the 5 rats had minimal renal tubular degeneration, and there were no changes in BUN or creatinine.”
BackgroundMethodInfluential
Metadata
- Authors
- Rudmann, D. G., Alston, J. T., Hanson, J. C., & Heidel, S.
- Affiliations
- Eli Lilly (United States) (US)
- Covance (United States) (US)
- Corresponding author
- Rudmann, Daniel G.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2013-06-20
- Volume
- 41
- Issue
- 7
- Pages
- 970-983
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2126061397
- Cited by
- 170
- References
- 18
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 17 · 2022: 19 · 2021: 13 · 2020: 12 · 2019: 21 · 2018: 20 · 2017: 13 · 2016: 9 · 2015: 10 · 2014: 14 · 2013: 2
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Toxicologic Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- tissue distribution, cytoplasmic vacuolization, molecular weight dependence, renal tubular epithelium, alveolar macrophages, Kupffer cells, choroid plexus epithelium, adaptive response, PEGylation
- MeSH terms
- Animals, Choroid Plexus, Immunohistochemistry, Kidney, Lung, Macaca fascicularis, Male, Molecular Weight, Polyethylene Glycols, Vacuoles, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.